Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
Semaglutide
In plain language
Semaglutide is a long-acting agonist (Ozempic, Wegovy) from Novo Nordisk. In STEP trials — average 14.9% weight loss over 68 weeks.
For researchers
Semaglutide is a long-acting synthetic receptor agonist developed by Novo Nordisk. Amino acid modification and a C-18 fatty acid chain bind it to albumin, extending half-life to ~1 week. Activates receptors in pancreas (insulin secretion), hypothalamus (satiety) and stomach (delayed emptying). Under trade names Ozempic/Rybelsus (diabetes) and Wegovy (obesity) -approved. STEP 1-5 clinical trials document average weight loss of 14.9% over 68 weeks. SUSTAIN series confirms efficacy in type 2 diabetes with HbA1c reduction up to -1.8%. Storage: -20°C lyophilized; reconstituted — 28 days at 2-8°C.
Scientific literature
Other peptides
Information about Semaglutide is based on published scientific research and is intended for research purposes. Not medical advice.
Products related to this peptide are for in vitro laboratory research only. Not approved for human consumption.